ClinicalTrials.gg
WithdrawnNCT04914533Updated Sep 17, 2026

Luminance RED for Canker Sores

An interventional study of Luminance RED Low Level Laser Therapy Device in Canker Sore, sponsored by ProofPilot. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by ProofPilot · Not applicable, Interventional, and Treatment

Why this study was withdrawn
did not launch
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Canker sores, also called aphthous ulcers, are small, shallow lesions that develop on the soft tissues in your mouth or at the base of your gums. Unlike cold sores, canker sores don't occur on the surface of your lips and they aren't contagious. They can be painful, however, and can make eating and talking difficult. Recurrent aphthous ulcer stomatitis (RAS) is characterized by recurrent bouts of solitary or multiple shallow painful ulcers, at intervals of a few months to a few days in patients who are otherwise well.

Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors, which trigger chemical changes.

The main medical usage of LLLT is for pain and inflammation reduction, promoting the regeneration of different tissues and preventing damage to tissues. With the use of the appropriate power (from 5 to 200mW) and wavelength (600-900nm), the therapy brings anti-inflammatory and analgesic results aiding in wound healing. The mechanism of action of LLLT may be very beneficial in the treatment of oral erosions and ulcers, however, very few studies have been performed on the treatment of RAS with LLLT. There are few reports on accelerated healing in erosive mucocutaneous disorders and they are often presented as a case series rather than large randomized clinical trials. The effects on skin wound healing and periodontal inflammation management with laser biostimulation suggest that this treatment modality may also be useful for oral erosive conditions.

This clinical trial aims to evaluate the effect of the Luminance RED device on the management of RAS.

02

Conditions studied

  • Canker Sore

Browse trials for

03

In context

Stomatitis, Aphthous

63 studies on the registry are indexed under Stomatitis, Aphthous; 17 are open to participants now.

Browse Stomatitis, Aphthous studies →

Lead sponsor

ProofPilot is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • 18 years and older.
  • Self report canker sore outbreaks once every 30 days or more frequent
  • Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • No previous experience of LLLT.
  • United States resident.
  • Willingness and ability to submit a $49 deposit using a credit card for the device.

Exclusion criteria

Exclusion Criteria:

  • Patients with a known systemic disease that predisposes them to RAS (e.g., Behçet disease) or undergoing systemic treatment for RAS.
  • The presence of a serious medical condition.
  • Currently known to be pregnant or breastfeeding
  • Patients treated with topical or systemic medication for RAS, such as therapy, antibiotics or analgesics during the previous month.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intervention Arm

    Luminance Red Treatment Arm

    Device: Luminance RED Low Level Laser Therapy Device

Interventions

  • DeviceLuminance RED Low Level Laser Therapy Device

    Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.

06

What researchers measure

Primary outcomes

  1. Change in Visual Analog Pain Scale

    daily score of canker sore pain

    Time frame: Baseline to day 18

  2. Change in Eating, drinking, and brushing teeth questionnaire

    score calculated on daily discomfort with eating, drinking and brushing teath

    Time frame: Baseline to day 18

Secondary outcomes

  1. Device retention

    Percentage of participants who decide to keep device

    Time frame: Day 21

07

Study locations

1 site
  • ProofPilot Virtual Online Trial (https://proofpilot.com)
    New York, New York 10003, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04914533
Lead sponsor
ProofPilot
Collaborators
Luminance RED
Responsible party
Sponsor
First posted
Jun 4, 2021
Start date
Jun 21, 2021 (estimated)
Primary completion
Sep 1, 2021
Completion
Sep 28, 2021
Last update
Sep 17, 2026

Study contacts

Matthew M Amsden
principal investigator · ProofPilot

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion